Evidence map›Paper›PMID 33259521›Full record

ArticlePloS one2020

Design, production and immunomodulatory potency of a novel allergen bioparticle.

Véronique Gomord, Virginie Stordeur, Anne-Catherine Fitchette, Elizabeth D Fixman, Guy Tropper, Lorna Garnier, Réjean Desgagnes, Sébastien Viel, Julie Couillard, Guillaume Beauverger and 5 more

Abstract read
In one paragraph

Article in PloS one, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed.

  1. Article
  2. Review
  3. Next-Generation Allergen-Specific Immunotherapy for Food Allergy.Clinical reviews in allergy & immunology · 2025
    Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Article
  10. Plant-based enveloped Ara h 2 bioparticles display exceptional hypo-allergenicity.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2023
    Article
  11. Article
  12. Article
  13. Article
  14. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Véronique GomordANGANY Innovation, Val de Reuil, France.ORCID 0000-0001-7062-9136
Virginie StordeurANGANY Innovation, Val de Reuil, France.
Anne-Catherine FitchetteANGANY Innovation, Val de Reuil, France.
Elizabeth D FixmanMcGill University Health Centre, Research Institute (RI MUHC), Montreal, Quebec, Canada.
Guy TropperANGANY Inc, Québec, Québec, Canada.ORCID 0000-0003-4884-9874
Lorna GarnierService d'Immunologie Biologique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.
Réjean DesgagnesANGANY Inc, Québec, Québec, Canada.
Sébastien VielService d'Immunologie Biologique, Hospices Civils de Lyon, Hôpital Lyon Sud, Pierre-Bénite, France.ORCID 0000-0002-5085-443X
Julie CouillardANGANY Inc, Québec, Québec, Canada.
Guillaume BeauvergerANGANY Innovation, Val de Reuil, France.
Sylvain TrepoutIR2 Inserm, Plateforme de microscopie électronique, INSERM US43/CNRS UMS2016, Institut Curie, Orsay, France.ORCID 0000-0002-5822-407X
Brian J WardMcGill University Health Centre, Research Institute (RI MUHC), Montreal, Quebec, Canada.
Ronald van ReeDepartment of Experimental Immunology, Molecular and Translational Allergy, Amsterdam, Netherlands.
Loic FayeANGANY Innovation, Val de Reuil, France.
Louis-P VézinaANGANY Inc, Québec, Québec, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Allergen immunotherapy (AIT) is the only disease-modifying treatment with evidence for sustained efficacy. However, it is poorly developed compared to symptomatic drugs. The main reasons come from treatment duration implying monthly injections during 3 to 5 years or daily sublingual use, and the risk of allergic side-effects. To become a more attractive alternative to lifelong symptomatic drug use, improvements to AIT are needed. Among the most promising new immunotherapy strategies is the use of bioparticles for the presentation of target antigen to the immune system as they can elicit strong T cell and B cell immune responses. Virus-like particles (VLPs) are a specific class of bioparticles in which the structural and immunogenic constituents are from viral origin. However, VLPs are ill-suited for use in AIT as their antigenicity is linked to structure. Recently, synthetic biology has been used to produce artificial modular bioparticles, in which supramolecular assemblies are made of elements from heterogeneous biological sources promoting the design and use of in vivo-assembling enveloped bioparticles for viral and non-viral antigens presentation. We have used a coiled-coil hybrid assembly for the design of an enveloped bioparticle (eBP) that present trimers of the Der p 2 allergen at its surface, This bioparticle was produced as recombinant and in vivo assembled eBPs in plant. This allergen biotherapeutic was used to demonstrate i) the capacity of plants to produce synthetic supramolecular allergen bioparticles, and ii) the immunomodulatory potential of naturally-assembled allergen bioparticles. Our results show that allergens exposed on eBPs induced a very strong IgG response consisting predominantly of IgG2a in favor of the TH1 response. Finally, our results demonstrate that rDer p 2 present on the surface of BPs show a very limited potential to stimulate the basophil degranulation of patient allergic to this allergen which is predictive of a high safety potential.

Indexed as

AllergensAmino Acid SequenceAnimalsAntigens, DermatophagoidesBasophilsBronchial HyperreactivityBronchoalveolar Lavage FluidDNAFemaleHumansHypersensitivityImmunizationImmunomodulationMice, Inbred BALB CNanoparticlesProtein Processing, Post-TranslationalAllergensAntigens, DermatophagoidesDerp2 allergen, Dermatophagoides pteronyssinusDNARecombinant Proteins

Identifiers

PMID33259521
PMCPMC7707610

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.